Compare SPCE & XBIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPCE | XBIT |
|---|---|---|
| Founded | 2017 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Transportation Services | Pharmaceuticals and Biotechnology |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 331.6M | 70.1M |
| IPO Year | 2017 | 2015 |
| Metric | SPCE | XBIT |
|---|---|---|
| Price | $2.96 | $2.18 |
| Analyst Decision | Hold | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $3.06 | N/A |
| AVG Volume (30 Days) | ★ 6.8M | 47.0K |
| Earning Date | 05-14-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 60.84 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,544,000.00 | N/A |
| Revenue This Year | $2,270.73 | N/A |
| Revenue Next Year | $880.03 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.13 | $2.09 |
| 52 Week High | $8.90 | $3.44 |
| Indicator | SPCE | XBIT |
|---|---|---|
| Relative Strength Index (RSI) | 51.21 | 37.39 |
| Support Level | $2.84 | N/A |
| Resistance Level | $3.39 | $2.46 |
| Average True Range (ATR) | 0.13 | 0.06 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 50.31 | 13.89 |
Virgin Galactic Holdings Inc is a United States-based vertically integrated aerospace company pioneering human spaceflight for private individuals & researchers, and it also manufactures air and space vehicles. Using technologies, the company is developing a spaceflight system designed to offer its customers a multi-day and transformative experience. This culminates in a spaceflight that includes views of Earth from space and several minutes of weightlessness that will launch from Spaceport America, New Mexico.
XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.